| Insights into the future of gastric acid suppression. | |
| | |
MedLine Citation:
|
PMID: 19713987 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The development of effective acid-suppression therapy (particularly PPIs) has revolutionized the treatment of acid-related diseases. Despite the overall effectiveness of these agents, they have some shortcomings, including a delayed onset of action, incomplete acid suppression in the majority of patients, and the need for ingestion before a meal to achieve maximal efficacy. Attempts to overcome these issues have included the development of isomeric PPIs (such as esomeprazole), alterations in drug delivery (such as delayed-release dexlansoprazole), and combined therapy with nonenterically coated PPIs and antacids (such as 'naked' omeprazole combined with sodium biocarbonate). Other acid-suppression agents in development or in late-phase trials include potassium-competitive acid blockers, new histamine receptor 2 antagonists, and gastrin antagonists. Although these agents could potentially achieve complete gastric acid suppression, risks may be associated with this level of suppression, including enteric infections and malabsorption of nutrients such as vitamin B(12), iron and calcium. This Review provides an update on the status of acid-suppression therapy and discusses directions for future research. |
| | |
Authors:
|
Kenneth R DeVault; Nicholas J Talley |
Related Documents
:
|
1356867 - The role of acid regulation in the treatment of nsaid-induced mucosal damage. 8344097 - Gastric emptying and bezoars in japanese. report of five cases. 314697 - Kinetics of acetylsalicylate and d-lactate transport across isolated frog gastric mucosa. 9409627 - Developmental toxicity study of inhaled acrylic acid in new zealand white rabbits. 785487 - Stability of injection solutions of vitamin b1. part 2: influence of lipoic acid. 7164027 - The procoagulant activity of partial thromboplastin extracts: the role of phosphatidyl ... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Nature reviews. Gastroenterology & hepatology Volume: 6 ISSN: 1759-5053 ISO Abbreviation: Nat Rev Gastroenterol Hepatol Publication Date: 2009 Sep |
Date Detail:
|
Created Date: 2009-08-28 Completed Date: 2009-11-17 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101500079 Medline TA: Nat Rev Gastroenterol Hepatol Country: England |
Other Details:
|
Languages: eng Pagination: 524-32 Citation Subset: IM |
Affiliation:
|
Department of Medicine, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32233, USA. devault@mayo.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anti-Ulcer Agents
/
pharmacology,
therapeutic use Gastric Acid / metabolism* Gastroesophageal Reflux / drug therapy, metabolism Histamine H2 Antagonists / pharmacology*, therapeutic use Humans Peptic Ulcer / drug therapy, metabolism Proton Pump Inhibitors / pharmacology*, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Ulcer Agents; 0/Histamine H2 Antagonists; 0/Proton Pump Inhibitors |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Mechanisms of growth impairment in pediatric Crohn's disease.
Next Document: Does PPI therapy predispose to Clostridium difficile infection?